To analyze the Radiation Therapy Oncology Group (RTOG) database of patients with glioblastoma and appraise whether outcome was influenced by time to initiation of radiation therapy (RT).
INTRODUCTION
Randomized trials have consistently shown the value of radiotherapy as part of the optimal management of glioblastoma multiforme (GBM). 1 Even modern series continue to show a statistically significant advantage in overall survival when radiotherapy alone is compared with best supportive care in various populations. 2 With its emergence as a standard of care for GBM, more attention has been devoted toward optimizing the delivery of radiotherapy. [3] [4] [5] A generally recognized, straightforward means of maximizing the efficacy of cancer treatments is the prompt initiation of such therapies. Indeed, among the first principles of oncology is the expeditious inauguration of cytotoxic therapy. 6 Because delay would be expected to have the most detrimental effect on the control of neoplasms with short doubling times, 7 patients with rapidly growing tumors such as GBM are theoretically the most vulnerable to negative consequences from delayed initiation of radiotherapy.
The relationship between the delay in radiotherapy and the outcome of radiotherapy has been explored [8] [9] [10] [11] [12] [13] in several tumor types (eg, breast, head and neck cancer) and less extensively in others (eg, lung, cervix cancer).
14, 15 To date, only one singleinstitutional experience has specifically addressed the delayed initiation of irradiation for GBM. 16 The current study was undertaken to explore this relationship by analyzing the database of the Radiation Therapy Oncology Group (RTOG), which provides prolonged follow-up from patients treated at multiple centers throughout the United States and Canada.
PATIENTS AND METHODS

Patient Population
Patients entered onto RTOG trials for biopsy-proven GBM constitute the study group for this article. These trials accrued 3,052 patients between 1974 and 2003. Primary treatment outcome reports from these trials have been previously published. [3] [4] [5] [17] [18] [19] [20] [21] Eligibility criteria were consistent in all of the studies: histologically confirmed supratentorial GBM; age of at least 18 years; normal hepatic, renal, and bone marrow function; and an interval of 6 weeks or less from surgery to initiation of radiotherapy. Ineligibility criteria included prior malignancies (except skin carcinomas), prior chemotherapy, or head and neck irradiation.
Protocol Summaries
The data for the present secondary analysis were culled from 16 studies. The treatment regimens of the trials included in this analysis are concisely described in Table 1 . Additional information is included on the official Web site of the RTOG (www.rtog.org).
Statistical Methods
The analyses are based on the data used for manuscripts or presentations. Because a new treatment standard for GBM (as manifest by a statistically significant survival advantage attributable to any given therapeutic arm) did not emerge from the respective studies, there was justification in pooling the data. Survival was measured from the date of study registration to the date of death or last follow-up, and survival rates were estimated using the KaplanMeier method. 22 The log-rank test was used to compare survival between the interval groups. 23 Outcome was assessed with the aid of the recursive partitioning technique (a method of building decision trees to model predictors) that was previously published by the RTOG. 24 The cutoff points used to define the groups (ie, intervals of Յ 2 weeks, Ͼ 2 to 3 weeks, Ͼ 3 to 4 weeks, Ͼ 4 weeks) were selected based on the distribution of intervals using percentiles (25%, 50%, 75%). A Cox proportional hazards model was also performed on this database using the variables common to all of the clinical trials that were included in the analysis.
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RESULTS
Patient Characteristics
Within the RTOG database for GBM, 3,052 patients were deemed suitable for the current analysis. Of these, 78 were rendered ineligible because of incomplete outcome data. In 119 cases, the chronology of treatment could not be determined (ie, the date of surgery was unknown for 70 patients; the initiation date of radiotherapy was unknown for 49 patients). Accordingly, 2,855 patients were included in this analysis. Figure 1 displays the overall survival with regard to the four interval (ie, time between surgery and initiation of radiotherapy) groups. The median survival time of those with the longest interval (ie, Ͼ 4 weeks) was significantly greater than the median survival time of the group with the shortest interval (ie, Յ 2 weeks; 12.5 months v 9.2 months; P Ͻ .0001). When this was examined by RPA stage, only RPA V showed the same trend.
Outcome Data
Twenty-one patients (0.7%) were enrolled at more than 6 weeks from time of surgery (average, 7.2 weeks; range, 6.1 to 10.4 weeks; median, 6.7 weeks). This number was too small to calculate any significant difference or trend as a separate interval group; however, interestingly, the average survival time for this group was higher than expected at 15 months.
Multivariate analysis of overall survival including time intervals (interval of Ͼ 4 weeks) and RPA stage showed that both variables are statistically significant factors with respect to overall survival (Table 3) . Treatment effects (whole-brain radiation therapy arms v radiation therapy arm and radiation therapy alone arms v radiation therapy plus radiosensitizers or chemotherapy arms), interaction terms with intervals, and RPA classes were also added to the multivariate analysis, and no significant effects were found. Table 4 was constructed to determine whether there was a disproportionate representation of progression during treatment or shortly thereafter among those who initiated radiotherapy within shorter intervals. No statistically significant differences in the rates of progression during treatment or in the month immediately after completion of radiation were observed across the four intervals (Յ 2 weeks, Ͼ 2 to 3 weeks, Ͼ 3 to 4 weeks, and Ͼ 4 weeks) studied.
DISCUSSION
The issue of prolonged waiting time for radiotherapy has been underscored in the literature for nearly two decades. The problem has now reached a state of crisis even in certain modern countries that enjoy a high quality of life by Western standards, such as Canada and Australia. 26, 27 Longer waiting times are a source of anxiety among patients and health care professionals because of the presumed deleterious effect of delay on tumor control.
The impact of delayed initiation of radiotherapy after surgery has been extensively studied in two settings: carcinoma of the breast as well as head and neck cancer. 28 In the case of breast cancer, the most common interval studied is 8 weeks between surgery (usually lumpectomy) and the first administration of radiotherapy. In most of the reported studies, 29-33 5-year locoregional recurrence rates in women treated with postoperative irradiation begun more than 8 weeks after surgery (approximately 9%) are significantly higher than those women treated within 8 weeks of surgery (approximately 6%). In several studies, 32,33 there also seemed to be an increased rate of distant metastases among women who received postoperative irradiation initiated more than 8 weeks after surgery. Among patients with unresected cancers of the head and neck, 1-month delays in the initiation of radiotherapy tended to increase the risk of local recurrence at 5 years.
12,13,34 For head and neck cancers managed with primary surgery followed by postoperative irradiation, [35] [36] [37] [38] there was a higher probability of locoregional recurrence in patients treated by irradiation begun more than 6 weeks after the operation. In one study, 14 actuarial 5-year survival rates were 61%, 46%, and 30% for patients with nonsmall-cell lung cancer who underwent radiation at 1 to 6 weeks, at 7 to 8 weeks, and at more than 8 weeks after surgery, respectively (P ϭ .046). Although the impact of delayed thoracic radiation has been studied in the context of small-cell and non-small-cell lung cancer, it is difficult to draw conclusions from the literature as a result of the common use of sequential regimens that interpose chemotherapy between surgery and radiotherapy. 39 To date, only one report has specifically examined the impact of delayed radiotherapy among patients with high-grade glioma. 16 In that study, three variables were identified that had a negative impact on survival: older age, reduced radiation dose, and delayed time from presentation to the radiation department until initiation of radiotherapy, where the hazard of death increased by 2% per day. Several caveats are worth underscoring. First, this report studied grade 3 as well as grade 4 gliomas. Although it was customary in the past to combine these two entities (even in some RTOG trials), 3, 5, 17, 19 it is likely that they behave as distinctly separate diseases. Second, the authors did not find a detrimental effect on survival with increased time interval between surgery and commencement of radiation; however, interestingly, they did find a significant effect of decreased survival in patients with longer waiting intervals between presentation to the radiation department and the initiation of radiation treatment. The RTOG database did not track the data point of presentation to the RT department. Third, these observations were made at a single institution. Part of the robustness of the RTOG database is derivative of the vast numbers of patients with retrievable follow-up information and III  83  11  129  16  119  16  113  21  IV  246  32  317  39  366  48  271  50  V  298  39  274  34  215  28  124  23  VI  127  17  82  10  53  7  28  5  Unknown 
the wide cross-section of medical centers participating, theoretically creating a better reflection of the broader reality. Finally, the RTOG mandated the relatively prompt initiation of treatment as an eligibility criterion for study participation (ie, maximal 6-week wait). The much wider window tolerated by Do et al (range, 1 to 62 days) may have had a negative impact on survival in certain cases. Notwithstanding, it is noteworthy that our results do not comport with trends recognized in the experience with carcinoma of the breast and head and neck cancer that are outlined above. As well, a recent report that assessed neoadjuvant temozolomide before radiotherapy for newly diagnosed patients with GBM was, by admission of the authors, inferior to standard concomitant radiotherapy plus temozolomide. 40 Whether this poor result by Chinot et al reflects a suboptimal radiation-drug interaction, a cohort that had an overrepresentation of patients expressing high levels of methylguanine methyltransferase, 41 or simply the consequence of introducing up to a 4-month delay secondary to the induction regimen is unclear.
Although 16 trials comprise the current report, none of these studies were designed a priori to address the specific issue of interval to initiation of radiation therapy after neurosurgical intervention. In fact, the ethical legitimacy of such a protocol design may be dubious at best, and it is unlikely that physicians would marshal the equipoise to conduct such a study. Thus despite the methodologic appeal of designing a prospective randomized trial to directly assess the impact of timing of radiotherapy, it is unlikely that such an effort will ever be mounted. As such, caution must be exercised in assessing whether a true effect of interval prolongation (either beneficial or detrimental) actually exists. Furthermore, although approximately 3,000 patients were entered into the current analysis, it is unclear that the retrospective nature of the review allowed sufficient power to exclude the possibility that delays in initiating radiotherapy may have had small but clinically meaningful deleterious effects.
The danger inherent in the delay of radiotherapy for patients with GBM seemed axiomatic. GBM is known to have a short doubling time. 42 In addition, like many tumors, GBM tends to invade locally, and the probability of achieving control is expected to decline as the tumor size increases.
7 Accordingly, we were surprised to see that our data did not lend support to this expectation and even yielded a result that was counterintuitive.
It is difficult to propose a plausible mechanism for an association between delayed therapy and improved survival in the treatment of GBM. We explored an alternative explanation, which posits that we were detecting a pragmatic epiphenomenon rather than a true biologic reality. Physician's intuition may have lead to expedited treatment for those patients who looked particularly fragile. If indeed, such patients went on to experience treatment failure quickly then we have simply used exotic statistical techniques to validate the astute judgment of clinicians who selected patients for prompt treatment on the basis of their clinical judgment that therapeutic intervention was required expeditiously. In other words, given the finite resources in many systems, physicians may have chosen to hasten the initiation of treatment for patients with the most advanced tumors when circumstances did not allow all patients to be treated with equal immediacy. As seen in Table 2 , there is a larger number of patients with Karnofsky Performance Score of 70 or less/Zubrod score of 3 to 4 in the group radiated earlier; likewise, there is an overrepresentation of patients undergoing biopsy in the groups of patients who underwent radiation earlier.
A surrogate means of checking the hypothesis that physicians treated patients with poorer prognostic factors differently was probed, as displayed in Table 4 , by evaluating for early tumor progression as correlating with earlier initiation of radiation therapy. However, in assessing these data, it is impossible to conclude that the more aggressive tumors (as manifest by a propensity to recur during therapy or within a month after completion) were overrepresented in the groups with the shortest intervals between surgery and initiation of radiotherapy.
Finally, there may be a detrimental effect to the injured organ (the brain) when treated with radiation too soon after the primary insult of surgery. Hypoxia from surgical manipulation and edema in the immediate postoperative period may diminish radiosensitivity.
Data from a study using rat models to examine brain surgery followed by radiation at differing onsets (also using controls without radiation) suggests that early initiation of radiation (within 1 to 2 weeks) after surgery, compared with 3 weeks or more, may result in higher levels of tissue damage. 43 In summary, within the relatively narrow temporal limits (6 weeks) of initiating radiotherapy after surgery that were permitted by Overall Survival (%) the RTOG in the trials reviewed, we were unable to uncover a disadvantage associated with delayed radiotherapy. However, it is difficult to construct a rationale for the conscious implementation of such delays. Additionally, treatment initiated beyond 6 weeks postoperatively may well be detrimental, but it is beyond the scope of our observations, and it is not feasible to design a prospective trial to test this hypothesis. Although we are disinclined to recommend deliberately forestalling radiotherapy among patients suffering from GBM, physicians may be able to reassure those patients who are waiting for treatment to commence that cancer control is unlikely to be compromised so long as the guidelines proposed by the RTOG investigators are respected. 
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